The earnings call for Doximity showed robust performance with significant revenue growth, improved EBITDA margins, and strong engagement metrics. The success of new products and the client portal contributed positively, although concerns about Q4 revenue growth and stability in the health system business were noted.

Company Guidance

During the Doximity Q2 2025 earnings call, the company provided robust financial guidance that exceeded expectations, highlighting key metrics and growth drivers. Doximity reported $137 million in revenue for the quarter, marking a 20% year-on-year growth and a 7% beat from the high end of their guidance. The adjusted EBITDA margin reached a record 56%, translating to $76 million, which was 41% higher year-over-year and 20% above guidance. The company observed a net revenue retention rate of 116%, up from 114% the previous year, with the top 20 customers showing a retention rate of 124%. Doximity's guidance for Q3 2025 included a revenue range of $152 million to $153 million and an adjusted EBITDA between $83 million and $84 million. For the full fiscal year, revenue is expected to be between $535 million and $540 million, with an adjusted EBITDA margin of 51%. The company attributed its success to strong upsell seasons, the client portal's rollout, and new product traction, particularly in workflow-related modules, which accounted for 20% of pharma sales.

Strong Revenue Growth

Doximity reported $137 million in revenue for Q2 2025, representing a 20% year-on-year growth and a 7% beat from the high end of their guidance range.

Record Adjusted EBITDA Margin

The company achieved a record adjusted EBITDA margin of 56%, or $76 million, which is a 41% increase year-on-year and 20% above the high end of their guidance.

Network Growth and Engagement

Q2 was a record engagement quarter with double-digit year-over-year growth in unique active users on a quarterly, monthly, weekly, and daily basis.

Pharma Sales and Client Portal Success

20% of pharma sales in Q2 came from workflow-related modules. The client portal is now open to more than 40% of pharma brand clients, driving strong sales growth and upsells.

Financial Outlook and Guidance Increase

For the full fiscal year, Doximity expects revenue in the range of $535 million to $540 million, representing a 13% growth at the midpoint, an increase of roughly 4% or $19 million at the midpoint after Q2 guidance outperformance.

---

Doximity (DOCS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DOCS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 06, 2025	2025 (Q3)	0.34 / -	0.29	―	―	―
Nov 07, 2024	2025 (Q2)	0.26 / 0.30	0.22	36.36% (+0.08)	―
Aug 08, 2024	2025 (Q1)	0.22 / 0.28	0.19	47.37% (+0.09)	―
May 16, 2024	2024 (Q4)	0.20 / 0.25	0.2	25.00% (+0.05)	―
Feb 08, 2024	2024 (Q3)	0.24 / 0.29	0.22	31.82% (+0.07)	―
Nov 09, 2023	2024 (Q2)	0.17 / 0.22	0.17	29.41% (+0.05)	―
Aug 08, 2023	2024 (Q1)	0.14 / 0.19	0.14	35.71% (+0.05)	―
May 16, 2023	2023 (Q4)	0.17 / 0.20	0.21	-4.76% (>-0.01)	―
Feb 09, 2023	2023 (Q3)	0.18 / 0.22	0.29	-24.14% (-0.07)	―
Nov 10, 2022	2023 (Q2)	0.15 / 0.17	0.19	-10.53% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DOCS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$43.42	$58.25	+34.15%
Aug 08, 2024	$25.66	$35.60	+38.74%
May 16, 2024	$23.74	$28.03	+18.07%
Feb 08, 2024	$28.24	$28.59	+1.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---